Publications by authors named "Sylvie D Freeman"

Claim this Profile
2
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
Jacqueline Cloos, Peter J M Valk, Christian Thiede, Konstanze Döhner, Gail J Roboz, Sylvie D Freeman

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Sylvie D Freeman

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Jad Othman, Nicola Potter, Sylvie D Freeman, Nicholas McCarthy, Jelena Jovanovic

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel.
Sa A Wang, Leonor Arenillas, Francesco Buccisano, Monika Bruggemann, Wolfgang Kern, Sylvie D Freeman

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.
Michael Boyiadzis, Andrew H Wei, Bruno Paiva, Sylvie D Freeman, Gertjan Kaspers

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Fadimana Kaya, Findlay Bewicke-Copley, Juho J Miettinen, Pedro Casado, Eve Leddy, Sylvie D Freeman

Leukemia· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.
Nigel H Russell, Abin Thomas, Sylvie D Freeman

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.
Nicola Potter, Jelena Jovanovic, Adam Ivey, Jad Othman, Abin Thomas, Sylvie D Freeman

Lancet Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Nigel H Russell, Abin Thomas, Robert K Hills, Ian Thomas, Amanda Gilkes, Sylvie D Freeman

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Stratification in Older Intensively Treated Patients With AML.
Jurjen Versluis, Marlen Metzner, Ariel Wang, Patrycja Gradowska, Abin Thomas, Sylvie D Freeman

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, Francesco Buccisano, Lok Lam Ngai

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Sylvie D Freeman

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With and Mutations.
Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, Richard Dillon, Steven Knapper, Sylvie D Freeman

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Jacob S Appelbaum, Andrew H Wei, Sumithra J Mandrekar, Ing S Tiong, Chong Chyn Chua, Sylvie D Freeman

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie D Freeman

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AML in the elderly-A global view.
Peter Hokland, Isolda I Fernández, Sylvie D Freeman, Bjørn T Gjertsen, Jie Jin

Br J Haematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Sylvie D Freeman, Abin Thomas, Ian Thomas, Robert K Hills, Paresh Vyas

Blood· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Jad Othman, Nicola Potter, Katya Mokretar, David Taussig, Anjum Khan, Sylvie D Freeman

Leukemia· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Rory M Shallis, Naval Daver, Jessica K Altman, Rami S Komrokji, Daniel A Pollyea, Sylvie D Freeman

Lancet Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D Freeman

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.
Eduard Schulz, Peter D Aplan, Sylvie D Freeman, Steven Z Pavletic

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute myeloid leukaemia.
Courtney D DiNardo, Harry P Erba, Sylvie D Freeman, Andrew H Wei

Lancet· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
Nicholas J Short, Chenqi Fu, Donald A Berry, Roland B Walter, Sylvie D Freeman

Leukemia· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transplant in older adults with AML: genomic wheat and chaff.
Sylvie D Freeman, Peter Valk

Blood· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis